Selected research
Industry Research
Cyclin Dependent Kinase 1 Industry Research Report 2026
Market perspective
The global Cyclin Dependent Kinase 1 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Cyclin Dependent Kinase 1 is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Cyclin Dependent Kinase 1 is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Cyclin Dependent Kinase 1 is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Cyclin Dependent Kinase 1 include Tragara Pharmaceuticals Inc, Tiziana Life Sciences Plc, Presage Biosciences Inc, ChoDang Pharm Co Ltd and Astex Pharmaceuticals Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Cyclin Dependent Kinase 1 market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cyclin Dependent Kinase 1 Market by Company
Tragara Pharmaceuticals Inc
Tiziana Life Sciences Plc
Presage Biosciences Inc
ChoDang Pharm Co Ltd
Astex Pharmaceuticals Inc
Cyclin Dependent Kinase 1 Segment by Type
Milciclib
CD-650
AT-7519
Others
Cyclin Dependent Kinase 1 Segment by Application
Relapsed Chronic Lymphocytic Leukemia
Lymphoma
Gliosarcoma
Others
Cyclin Dependent Kinase 1 Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cyclin Dependent Kinase 1 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cyclin Dependent Kinase 1 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cyclin Dependent Kinase 1.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Cyclin Dependent Kinase 1 manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Cyclin Dependent Kinase 1 by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Cyclin Dependent Kinase 1 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Milciclib
- CD-650
- AT-7519
- Others
Applications
- Relapsed Chronic Lymphocytic Leukemia
- Lymphoma
- Gliosarcoma
- Others
Companies covered
- Tragara Pharmaceuticals Inc
- Tiziana Life Sciences Plc
- Presage Biosciences Inc
- ChoDang Pharm Co Ltd
- Astex Pharmaceuticals Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Cyclin Dependent Kinase 1 Market Size (2021-2032)
- 2.2.2 Global Cyclin Dependent Kinase 1 Sales (2021-2032)
- 2.2.3 Global Cyclin Dependent Kinase 1 Market Average Price (2021-2032)
- 2.3 Cyclin Dependent Kinase 1 by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Milciclib
- 2.3.3 CD-650
- 2.3.4 AT-7519
- 2.3.5 Others
- 2.4 Cyclin Dependent Kinase 1 by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Relapsed Chronic Lymphocytic Leukemia
- 2.4.3 Lymphoma
- 2.4.4 Gliosarcoma
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Cyclin Dependent Kinase 1 Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Cyclin Dependent Kinase 1 Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Cyclin Dependent Kinase 1 Revenue of Manufacturers (2021-2026)
- 3.4 Global Cyclin Dependent Kinase 1 Average Price by Manufacturers (2021-2026)
- 3.5 Global Cyclin Dependent Kinase 1 Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Cyclin Dependent Kinase 1, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Cyclin Dependent Kinase 1, Product Type & Application
- 3.8 Global Manufacturers of Cyclin Dependent Kinase 1, Established Date
- 3.9 Global Cyclin Dependent Kinase 1 Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Tragara Pharmaceuticals Inc
- 4.1.1 Tragara Pharmaceuticals Inc Company Information
- 4.1.2 Tragara Pharmaceuticals Inc Business Overview
- 4.1.3 Tragara Pharmaceuticals Inc Cyclin Dependent Kinase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Tragara Pharmaceuticals Inc Cyclin Dependent Kinase 1 Product Portfolio
- 4.1.5 Tragara Pharmaceuticals Inc Recent Developments
- 4.2 Tiziana Life Sciences Plc
- 4.2.1 Tiziana Life Sciences Plc Company Information
- 4.2.2 Tiziana Life Sciences Plc Business Overview
- 4.2.3 Tiziana Life Sciences Plc Cyclin Dependent Kinase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Tiziana Life Sciences Plc Cyclin Dependent Kinase 1 Product Portfolio
- 4.2.5 Tiziana Life Sciences Plc Recent Developments
- 4.3 Presage Biosciences Inc
- 4.3.1 Presage Biosciences Inc Company Information
- 4.3.2 Presage Biosciences Inc Business Overview
- 4.3.3 Presage Biosciences Inc Cyclin Dependent Kinase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Presage Biosciences Inc Cyclin Dependent Kinase 1 Product Portfolio
- 4.3.5 Presage Biosciences Inc Recent Developments
- 4.4 ChoDang Pharm Co Ltd
- 4.4.1 ChoDang Pharm Co Ltd Company Information
- 4.4.2 ChoDang Pharm Co Ltd Business Overview
- 4.4.3 ChoDang Pharm Co Ltd Cyclin Dependent Kinase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 ChoDang Pharm Co Ltd Cyclin Dependent Kinase 1 Product Portfolio
- 4.4.5 ChoDang Pharm Co Ltd Recent Developments
- 4.5 Astex Pharmaceuticals Inc
- 4.5.1 Astex Pharmaceuticals Inc Company Information
- 4.5.2 Astex Pharmaceuticals Inc Business Overview
- 4.5.3 Astex Pharmaceuticals Inc Cyclin Dependent Kinase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Astex Pharmaceuticals Inc Cyclin Dependent Kinase 1 Product Portfolio
- 4.5.5 Astex Pharmaceuticals Inc Recent Developments
5 Global Cyclin Dependent Kinase 1 Market Scenario by Region
- 5.1 Global Cyclin Dependent Kinase 1 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Cyclin Dependent Kinase 1 Sales by Region: 2021-2032
- 5.2.1 Global Cyclin Dependent Kinase 1 Sales by Region: 2021-2026
- 5.2.2 Global Cyclin Dependent Kinase 1 Sales by Region: 2027-2032
- 5.3 Global Cyclin Dependent Kinase 1 Revenue by Region: 2021-2032
- 5.3.1 Global Cyclin Dependent Kinase 1 Revenue by Region: 2021-2026
- 5.3.2 Global Cyclin Dependent Kinase 1 Revenue by Region: 2027-2032
- 5.4 North America Cyclin Dependent Kinase 1 Market Facts & Figures by Country
- 5.4.1 North America Cyclin Dependent Kinase 1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Cyclin Dependent Kinase 1 Sales by Country (2021-2032)
- 5.4.3 North America Cyclin Dependent Kinase 1 Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Cyclin Dependent Kinase 1 Market Facts & Figures by Country
- 5.5.1 Europe Cyclin Dependent Kinase 1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Cyclin Dependent Kinase 1 Sales by Country (2021-2032)
- 5.5.3 Europe Cyclin Dependent Kinase 1 Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Cyclin Dependent Kinase 1 Market Facts & Figures by Country
- 5.6.1 Asia Pacific Cyclin Dependent Kinase 1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Cyclin Dependent Kinase 1 Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Cyclin Dependent Kinase 1 Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Cyclin Dependent Kinase 1 Market Facts & Figures by Country
- 5.7.1 South America Cyclin Dependent Kinase 1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Cyclin Dependent Kinase 1 Sales by Country (2021-2032)
- 5.7.3 South America Cyclin Dependent Kinase 1 Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Cyclin Dependent Kinase 1 Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Cyclin Dependent Kinase 1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Cyclin Dependent Kinase 1 Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Cyclin Dependent Kinase 1 Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Cyclin Dependent Kinase 1 Sales by Type (2021-2032)
- 6.1.1 Global Cyclin Dependent Kinase 1 Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Cyclin Dependent Kinase 1 Sales Market Share by Type (2021-2032)
- 6.2 Global Cyclin Dependent Kinase 1 Revenue by Type (2021-2032)
- 6.2.1 Global Cyclin Dependent Kinase 1 Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Cyclin Dependent Kinase 1 Revenue Market Share by Type (2021-2032)
- 6.3 Global Cyclin Dependent Kinase 1 Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Cyclin Dependent Kinase 1 Sales by Application (2021-2032)
- 7.1.1 Global Cyclin Dependent Kinase 1 Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Cyclin Dependent Kinase 1 Sales Market Share by Application (2021-2032)
- 7.2 Global Cyclin Dependent Kinase 1 Revenue by Application (2021-2032)
- 7.2.1 Global Cyclin Dependent Kinase 1 Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Cyclin Dependent Kinase 1 Revenue Market Share by Application (2021-2032)
- 7.3 Global Cyclin Dependent Kinase 1 Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Cyclin Dependent Kinase 1 Value Chain Analysis
- 8.1.1 Cyclin Dependent Kinase 1 Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Cyclin Dependent Kinase 1 Production Mode & Process
- 8.2 Cyclin Dependent Kinase 1 Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Cyclin Dependent Kinase 1 Distributors
- 8.2.3 Cyclin Dependent Kinase 1 Customers
9 Global Cyclin Dependent Kinase 1 Analyzing Market Dynamics
- 9.1 Cyclin Dependent Kinase 1 Industry Trends
- 9.2 Cyclin Dependent Kinase 1 Industry Drivers
- 9.3 Cyclin Dependent Kinase 1 Industry Opportunities and Challenges
- 9.4 Cyclin Dependent Kinase 1 Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst